Screener
Tarsus Pharmaceuticals, Inc. TARS Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Intangible assets, net | 6,885 | 7,366 |
| Operating lease right-of-use assets | 9,911 | 10,080 |
| Long-term investments | 6,682 | 3,870 |
| Other assets | 660 | 1,861 |
| Total assets | $611,142 | $562,158 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $40,141 | $16,387 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s other non-current assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported other non-current assets of $660K in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s other non-current assets changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s other non-current assets decreased by 45.6% year-over-year, from $1.21M to $660K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s other non-current assets?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s other non-current assets has grown at a 107.8% compound annual growth rate (CAGR), from $48K to $1.86M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude